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Abstract
Background: Triple-negative breast cancer (TNBC) is associated with an aggressive clinical course due to the
lack of therapeutic targets. Therefore, identifying reliable prognostic biomarkers and novel therapeutic targets
for patients with TNBC is required. Proline, glutamic acid, leucine rich protein 1 (PELP1) is a novel steroidal
receptor co-regulator, functioning as an oncogene and its expression is maintained in estrogen receptor (ER)
negative breast cancers. PELP1 has been proposed as a prognostic biomarker in hormone-related cancers,
including luminal-type breast cancers, but its significance in TNBC has not been studied.
Methods: PELP1 immunoreactivity was evaluated using immunohistochemistry in 129 patients with TNBC.
Results were correlated with clinicopathological variables including patient’s age, tumor size, lymph node
stage, tumor grade, clinical stage, histological type, Ki-67 LI, as well as clinical outcome of the patients,
including disease-free survival (DFS) and overall survival (OS).
Results: PELP1 was localized predominantly in the nuclei of carcinoma cells in TNBC. With the exception of a positive
correlation between PELP1 protein expression and lymph node stage (p = 0.027), no significant associations between
PELP1 protein expression and other clinicopathological variables, including DFS and OS, were found. However, when
PELP1 and Ki-67 LI were grouped together, we found that patients in the PELP1/Ki-67 double high group (n = 48)
demonstrated significantly reduced DFS (p = 0.005, log rank test) and OS (p = 0.002, log rank test) than others (n = 81).
Multivariable analysis supported PELP1/Ki-67 double high expression as an independent prognostic factor in patients
with TNBC, with an adjusted hazard ratio of 2.020 for recurrence (95 % CL, 1.022–3.990; p = 0.043) and of 2.380 for
death (95 % CL, 1.138–4.978; p = 0.021).
Conclusions: We found that evaluating both PELP1 and Ki-67 expression in TNBC could enhance the prognostic
sensitivity of the two biomarkers. Therefore, we propose that PELP1/Ki-67 double high expression in tumors is an
independent prognostic factor for predicting a poor outcome for patients with TNBC.
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Background
Breast cancer is a heterogeneous disease that harbors
various genetic alterations allowing it to be classified
into distinct molecular subtypes that respond differently
to therapy and are associated with various clinical out-
comes [1]. Triple-negative breast cancer (TNBC), one of
the three IHC-defined subtypes routinely assessed in
clinical practice, is characterized by the lack of expression
of estrogen receptor alpha (ERα) and progesterone recep-
tor (PR), as well as non-amplified levels of human epider-
mal growth factor receptor 2 (HER-2) in carcinoma cells.
The TNBC subtype is generally associated with an aggres-
sive clinical course and worse prognosis due to the lack of
available targeted therapeutic measures, such as aromatase
inhibitors or trastuzumab treatment [2].
Traditional prognostic parameters used in the assess-
ment of breast cancer outcomes, such as histological type,
lymph node stage, and Nottingham prognosis index, may
influence the prognosis of individual TNBC patients.
However, as a group, TNBC patients with similar prognos-
tic parameters often experience rather different clinical
outcomes [3]. Therefore, it has become important to iden-
tify new prognostic biomarkers for TNBC patients. Several
factors such as the mesenchymal-to-epithelial transition
factor [4], Lewis X [5], and breast cancer type 1 suscepti-
bility protein (BRCA1) [6] have been proposed as prog-
nostic markers for TNBC patients, but their predictive
significance is uncertain.
Proline, glutamic acid, leucine rich protein 1 (PELP1;
also known as a modulator of non-genomic activity of
the estrogen receptor) is a novel steroidal receptor co-
regulator. Of great interest, in contrast to other steroidal
receptor co-regulators, PELP1 is involved in both gen-
omic and non-genomic functions of steroidal signaling
and exhibits oncogenic properties [7]. Specifically,
PELP1 overexpression has been reported to induce the
malignant transformation of normal cells, accelerate cell
cycle progression, promote tumor cell proliferation, and
enhance the migration and invasion of tumor cells [8].
PELP1 was initially identified as a co-regulator of ERα,
but its expression is also remarkably high in ERα-
negative breast cancers [9, 10]. Additionally, reduction
of PELP1 in ERα-negative breast cancer cell lines re-
duced proliferation and tumor metastasis, suggesting a
role for PELP1 in tumor progression [10]. Therefore,
PELP1 is postulated to function independently of ERα in
breast carcinoma cells.
Several studies also proposed PELP1 as a prognostic
biomarker in hormone-related cancers, including endo-
metrial [11], ovarian [12], colorectal [13], and luminal-
type breast carcinomas [14]. However, the predictive value
of PELP1 in TNBC has remained unclear. Therefore, in
this study, we retrospectively assessed PELP1 immunore-
activity in 129 patients with TNBC, and correlated the
status of PELP1 independently, or in combination with




TNBC was defined as breast carcinomas with negative
expression of ERα (positive tumor nuclei <1 % on im-
munohistochemistry), PR (positive tumor nuclei <1 %
on immunohistochemistry), and HER-2 expression
(HercepTest score <2 on immunohistochemistry or
HercepTest score = 2 on immunohistochemistry with
HER2/CEP17 ratio <2.2 by fluorescence in situ
hybridization). A total of 159 cases of patients diagnosed
as TNBC at The Fifth Affiliated Hospital of Harbin Med-
ical University, Daqing Oilfield General Hospital and
Daqing Longnan Hospital were collected. Clinical infor-
mation (including patient’s age, tumor size, lymph node
stage, tumor grade, histological type, clinical stage), patho-
logical biomarkers information [including status of ER,
PR, HER-2, and Ki-67 label index (Ki-67 LI) (Ki-67 LI was
defined as the percentage of tumor cells showed nuclear
immunoreactivity with MIB-1)], and primary treatment
(including surgery, chemotherapy, and radiotherapy) were
retrieved from the medical records at these three in-
stitutions. Twelve patients were excluded from the
study cohort because of gender (male), or acceptance
of neo-adjuvant chemotherapy. The pathological slides
of the remaining 147 patients were reviewed by two
of the authors (JLD and BSZ.) blinded to the clinical
and follow-up data. Subsequently, 18 were excluded
for discordance between the reviewers, leaving 129
patients in the study. These cases consisted of 49 pa-
tients diagnosed at The Fifth Affiliated Hospital of
Harbin Medical University from 2001 to 2011, 45
cases diagnosed at Daqing Longnan Hospital from
2002 to 2010, and 35 patients diagnosed at Daqing
Oilfield General Hospital from 2004 to 2011. Forma-
lin fixed, paraffin-embedded surgical excisional tissue
blocks from each selected patient were collected for
detecting PELP1 protein expression. The protocol of
this study is in accordance with the Helsinki Declar-
ation and was approved by the institutional review
board of Harbin Medical University. The approvals
for this study were obtained from all the three hospi-
tals involved, written informed consent was obtained
from all participants.
Immunohistochemistry (IHC)
For immunohistochemistry, all samples were prepared as
5-μm-thick serial sections mounted on glass slides. Slides
were deparaffinized with xylene and rehydrated on alcohol
gradients. Endogenetic peroxidase was blocked with 3 %
hydrogen peroxide-methanol for 30 minutes. For antigen
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retrieval, specimens were heated for 15 minutes in 10-
mM citrate buffer (pH6.0) by microwaving (500 W).
Polyclonal antibody against PELP1 (Cat. IHC-00013,
Bethyl Laboratories, Inc. Montgomery, AL, USA) was
applied at an optimized dilution of 1:200 at 4 °C overnight.
Real Envision Detection system (DAKO, Denmark) was
used instead of the traditional secondary antibody, sec-
tions were visualized with the chromogen DAB and coun-
terstained with hematoxylin. The specificity of the PELP1
antibody was checked by western blot using a standard
protocol. For quality control, a breast cancer specimen
with definite PELP1 protein expression was used as a posi-
tive control, while a negative control was performed by
omitting the primary antibody and substituting it with
antibody dilution buffer (DAKO, Denmark).
The PELP1 immunoreactivity was evaluated independ-
ently by two of the authors (ML and SWC), both of
whom were blinded to the clinical and follow up data of
the samples. H-score was used to quantify the immuno-
reactivity of PELP1, as previously described [14]. In brief,
PELP1 staining intensity was scored as 0, 1, 2, and 3,
and the percentage of positive cells was determined for
each score to produce a final score in the range 0–300.
The optimized cutoff points in the Habashy et al.
study were also adopted for this study, the cut-off
points were defined using the X-tile program, and the
immunoreactivity of PELP1 were classified into nega-
tive (H-score <5), moderate (5 ≤H-score <170) and
strong (170 ≤H-score) [14].
Statistical analysis
Statistical analysis was performed using SPSS 17.0 statis-
tical software (Chicago, IL, USA). Association between
PELP1 protein expression and different clinicopathologi-
cal variables was studied using the chi-square test. The
primary endpoint of this study was disease-free survival
(DFS), and the second endpoint was overall survival
(OS). DFS was defined as the period from the date of
primary surgery to the date of diagnosis as local or
distant recurrence, OS was defined as the period be-
tween the date of primary surgery and the date of
death (from any cause). Univariable survival curves
were estimated by the Kaplan-Meier method and
tested with the log rank test. Multivariable analysis
for DFS and OS were performed using the Cox propor-




The median age of the patients at the time of their first
surgery was 50 years (range 26–75). The median follow-
up was 40 months (range 2–87). At the end of this
study, 29.4 % (38/129) of the patients experienced local/
Table 1 Patient clinical pathological variables
Clinical pathological variables number
Age (years)
≤50 69 (53.5 %)
>50 60 (46.5 %)
Tumor size (cm)a
≤2 31 (24.0 %)
>2, ≤5 74 (57.4 %)
>5 22 (17.1 %)
Unavailable 2 (1.6 %)
Lymph node stage
negative 65 (50.4 %)
positive 64 (49.6 %)
Grade
G1 24 (18.6 %)
G2 30 (23.3 %)
G3 75 (58.1 %)
Clinical stagea
I 19 (14.7 %)
II 62 (48.1 %)
III and IV 46 (35.7 %)
Unavailable 2 (1.6 %)
Histological type
IDC 101 (78.3 %)
ILC 18 (14.0 %)
Others 10 (7.8 %)
Ki-67 LI
Low (≤14 %) 39 (30.2 %)
High (>14 %) 90 (69.8 %)
Chemotherapy
AC 45 (34.9 %)
AC-T 72 (55.8 %)
Others 10 (7.8 %)
None 2 (1.6 %)
Radiotherapy
No 67 (51.9 %)
Yes 62 (48.1 %)
Cohort
FAHHMU 49 (38.0 %)
DLH 45 (34.9 %)
DOGH 35 (27.1 %)
Abbreviations: LN, lymph node; IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; Ki-67 LI, Ki-67 label index; AC, Adriamycin/Cyclophosphamide;
AC-T, Adriamycin/Cyclophosphamide-Taxol; FAHHMU, The Fifth Affiliated Hospital
of Harbin Medical University; DLG, Daqing Longnan Hospital; DOGH, Daqing
Oilfield General Hospital
Note: afor the variable, data for two cases are unavailable from medical records
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distant recurrence, and 24.8 % (32/129) died. The clini-
copathological variables of the patients are summarized
in Table 1. For all collected variables, no significant dif-
ference was found among the cohorts from The Fifth
Affiliated Hospital of Harbin Medical University, Daqing
Longnan Hospital, and Daqing Oilfield General Hospital
(data not shown).
PELP1 protein expression
PELP1 protein immunostaining was exclusively local-
ized to the nuclei of tumor cells, with no cytoplas-
mic staining observed in any sample in this cohort.
In some cases, weak nuclear immunostaining of
PELP1 could also be observed in ductal epithelial
cells and fibroblasts of the surrounding normal tis-
sues (Fig. 1). Among our TNBC cohort, the lowest
H-score of PELP1 was 12. Consequently, none of the
samples were classified into the negative group,
45.7 % (59/129) of the cases were classified into the
moderate group and 54.3 % (70/129) were classified
into the strong group. Thus, two groupings emerged:
a PELP low group and a PELP high group, corre-
sponding to the Habashy et al. moderate and strong
classifications, respectively [14].
Correlation of PELP1 protein expression with other
clinicopathological variables
The expression of PELP1 in TNBC was compared to
clinicopathological variables including patient’s age,
tumor size, lymph node stage, tumor grade, clinical
stage, histological type, Ki-67 LI, and primary treatment
to see if there were correlations between PELP1 and
these variables. The cut-off value for each of these vari-
ables was a standardized value that was in line with pre-
vious publications [15]. With the exception of a positive
correlation between PELP1 protein expression and
lymph node stage (p = 0.027), no significant association
between PELP1 protein expression and other clinico-
pathological variables was found (Table 2).
Clinicopathological variables and patient outcome
Kaplan–Meier survival analysis revealed that patients
with higher lymph node stage or clinical stage have sig-
nificantly reduced DFS and OS (Fig. 2a, b). No signifi-
cant association between the other observed variables
and patient survival were found, including the status of
PELP1 (Table 3), although patients in the high PELP1
group demonstrated a trend of reduced DFS and OS,
compared with those in the low PELP1 group (Fig. 2c).
PELP1 protein expression and patient outcome in TNBC
subgroups
To further explore the prognostic significance of PELP1
in TNBC, we subgrouped the patients according to age,
tumor size, lymph node stage, tumor grade, histological
type, clinical stage, Ki-67 LI, chemotherapy, and radio-
therapy, and correlations between PELP1 protein expres-
sion and patient’s outcome in the different subgroups
were examined using Kaplan–Meier analysis. In the sub-
group with tumor size ≤ 2 cm, patients with high PELP1
protein expression showed significantly shorter DFS
compared with those with low PELP1 expression
(Fig. 3a). In the subgroup with high Ki-67 LI (>14 %),
both DFS and OS of patients with high PELP1 expres-
sion were significantly shorter than those with low
PELP1 expression (Fig. 3b). No significant correlation
between PELP1 expression and patient’s outcome was
found in any other subgroup (Table 4).
Combining PELP1 status and Ki-67 LI as a prognostic
biomarker
Considering that we found a significant correlation be-
tween PELP1 status and DFS, as well as between PELP1
status and OS, but only in the high Ki-67 LI subgroup,
we further examined whether combining PELP1 status
and Ki-67 LI can be used as a prognostic biomarker for
the whole TNBC cohort. The patients were subgrouped
into four groups according to PELP1 status and Ki-67
LI: PELP1/Ki-67 double low, PELP1 low/Ki-67 high,
Fig. 1 Immunohistochemical staining of PELP1 in TNBC. Positive immunostaining of PELP1 mainly distributed in nuclei of tumor cells, no cytoplasmic
staining was found (a, b). Low grade lymph node stage TNBC showed weak PELP1 nuclear expression (a), High grade lymph node stage
TNBC showed strong PELP1 nuclear expression (b). PELP1 nuclear staining was absent in negative control (c). Bar = 50 μm.
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PELP1 high/ Ki-67 low, and PELP1/Ki-67 double high
groups, and submitted for univariate survival analysis.
For the four groups, Kaplan–Meier analysis showed a
significant difference related to DFS (p = 0.047) and OS
(p = 0.022). Additionally, this difference mainly existed
between PELP1/Ki-67 double high group and the others
(Fig. 4a). Subsequent analysis revealed that patients in
the PELP1/Ki-67 double high group (n = 48) had signifi-
cantly reduced DFS (p = 0.005, log rank test) and OS
(p = 0.002, log rank test) than others (n = 81) (Fig. 4b).
Multivariable analysis
The independent effect of PELP1/ Ki-67 double high
expression on DFS and OS was assessed using a multi-
variable Cox proportional hazards regression model,
adjusted for patient age, tumor size, lymph node stage,
tumor grade, and histological type. The analysis sup-
ported PELP1/Ki-67 double high expression as an inde-
pendent prognostic factor in patients with TNBC, with
an adjusted hazard ratio (HR) of 2.020 for recurrence
(95 % CL, 1.022–3.990; p = 0.043) and of 2.380 for
death (95 % CL, 1.138–4.978; p = 0.021) (Table 5).
Discussion
Although previous studies have shown that PELP1 func-
tions as an oncogene that is deregulated in breast cancer
[14, 16], little is known about the prognostic significance
of PELP1 in TNBC. Our study provided three new in-
sights into the predictive role of PELP1 in TNBC: first,
high PELP1 protein expression is correlated with posi-
tive lymph node status in TNBC; second, for the TNBC
patients presenting with small tumor size or high Ki-67
LI, high PELP1 protein expression in the tumor is asso-
ciated with a poor outcome; third, double high expres-
sion of PELP1 and Ki-67 in TNBC is associated with
poorer patient outcomes, and was found to be an inde-
pendent prognostic factor.
In our study, PELP1 was exclusively nuclear in
localization. This result is consistent with recent immuno-
histochemical studies using commercially available anti-
bodies against PELP1 in a variety of tissues [12, 14, 17].
However, PELP1 has been suggested to be involved in
both the nuclear-initiated and membrane-initiated action
of estrogen, and earlier IHC studies performed at the MD
Anderson Cancer Center also reported PELP1 to have
extensive cytoplasmic location in a panel of tumor
tissues [9, 11, 18, 19]. A possible explanation for this
discrepancy may lie in the different antibodies against
PELP1 used in these studies. Of note, the antibody used
in the IHC studies from the MD Anderson Cancer Center
was developed by the local laboratory, and was raised
by challenging a rabbit with a 19-mer peptide encoding
558–576 amino acids residues in the center of PELP1 [18].
However, most commercial antibodies against PELP1,
Table 2 Correlation between PELP1 protein expression and
clinicopathological variables in patients with TNBC
Variables n Status of PELP1 protein expression P-value
low high
Age (years)
≤50 69 31 (44.9 %) 38 (55.1 %) 0.843
>50 60 28 (46.7 %) 32 (53.3 %)
Tumor size (cm)a
≤2 31 13 (41.9 %) 18 (58.1 %) 0.635
>2, ≤5 74 33 (44.6 %) 41 (55.4 %)
>5 22 12(54.5 %) 10 (45.5 %)
Lymph node stage
negative 65 36 (55.4 %) 29 (44.6 %) 0.027
positive 64 23 (35.9 %) 41 (64.1 %)
Grade
G1 24 13 (54.2 %) 11 (45.8 %) 0.612
G2 30 14 (46.7 %) 16 (53.3 %)
G3 75 32 (42.7 %) 43 (57.3 %)
Clinical stagea
I 19 11 (57.9 %) 8 (42.1 %) 0.374
II 62 29 (46.8 %) 33 (53.2 %)
III and IV 46 18 (39.1 %) 28 (60.9 %)
Histological type
IDC 101 45 (44.6 %) 56 (55.4 %) 0.250
ILC 18 11 (61.1 %) 7 (38.9 %)
Others 10 3 (30.0 %) 7 (70.0 %)
Ki-67 LI
Low (≤14 %) 39 17 (43.6 %) 22 (56.4 %) 0.747
High (>14 %) 90 42 (46.7 %) 48 (53.3 %)
Chemotherapy
AC 45 22 (48.9 %) 23 (51.1 %) 0.945
AC-T 72 32 (44.4 %) 40 (55.6 %)
Others 10 4 (40.0 %) 6 (60.0 %)
None 2 1 (50.0 %) 1 (50.0 %)
Radiotherapy
No 67 30 (44.8 %) 37 (55.2 %) 0.820
Yes 62 29 (46.8 %) 33 (53.2 %)
Cohort
FAHHMU 49 22 (44.9 %) 27 (55.1 %) 0.820
DLH 45 21 (46.7 %) 24 (53.5 %)
DOGH 35 16 (45.7 %) 19 (54.3 %)
Abbreviations: LN, lymph node; IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; Ki-67 LI, Ki-67 label index; AC, Adriamycin/Cyclophosphamide;
AC-T, Adriamycin/Cyclophosphamide-Taxol; FAHHMU, The Fifth Affiliated
Hospital of Harbin Medical University; DOGH, Daqing Oilfield General Hospital
Note: afor the variable, data for two cases are unavailable from medical
records
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including the antibody used in this study (Bethyl Labora-
tory; Cat. IHC-00013), as well as that used in the Habashy
et al. study (Novus Biologicals; Cat.NB100-1749) [14], were
raised to recognize the epitopes between residues 1000–
1050 in the C-terminal of PELP1, which has been identified
as a region for PELP1 interaction with cytoplasmic pro-
teins, such as the p85 subunit of phosphatidylinositol 3-
kinase (PI3K) [18, 20]. Thus, the epitope recognized by
these commercially available antibodies might be masked
when PELP1 is localized in the cytoplasm, and leave only
nuclear immunostaining detectable by IHC.
H-score is the gold standard for quantifying nuclear
immunoreactivity of IHC specimens because it takes
into account both immunointensity and immunoreactiv-
ity, allowing an accurate approximation of the protein
content. Additionally, previous studies have used the H-
score approach to quantify PELP1 immunoreactivity
[14], which led us to adopt a similar approach for our
quantification of immunostaining of PELP1. PELP1 pro-
tein expression in our TNBC cohort (54.3 % ≥ 170) was
significantly higher compared with that of unselected
breast cancers (13.5 % ≥ 170) in the Habashy et al. study
Fig. 2 Clinicopathological variables and outcomes of patients with TNBC. Kaplan–Meier survival curve showed that TNBC patients with positive
lymph node metastasis had significantly reduced DFS (a1) and OS (a2); TNBC patients in stage III and IV also demonstrated significantly reduced
DFS (b1) and OS (b2); PELP1 was not associated with DFS or OS in TNBC patients when observed independently, although patients in the high
PELP1 group demonstrated a trend of reduced DFS (c1) and OS (c2), compared with those in the low PELP1 group.
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[14]. Although assessment of strong PELP1 expression
in the TNBC group is not available from the Habashy et
al. study, the positive correlation of PELP1 with expres-
sion of basal cytokeratin (CK-14, CK-5/6) and the nega-
tive correlation with ER and PR in unselected breast
cancer reported in that study suggested a relatively
higher expression of PELP1 in TNBC [14].
In our TNBC cohort, PELP1 protein expression
showed positive correlations with lymph node stage. Al-
though no association between PELP1 expression and
lymph node stage was found, the expression of PELP1
demonstrated to be positively correlated with distant
metastasis in the Habashy et al. study [14]. Several stud-
ies have suggested PELP1 may play an important role in
Table 3 Univariate analysis of DFS and OS according to clinicopathological variables
Variables DFS OS
χ2 P-value χ2 P-value
Age (years) ≤50 vs. >50 0.058 0.810 0.436 0.509
Tumor size (cm)a ≤2 vs. >2, ≤5 vs. >5 2.515 0.284 2.608 0.271
Lymph node stage negative vs. positive 11.706 0.001 8.803 0.003
Grade G1 vs. G2 vs. G3 4.764 0.092 3.204 0.201
Clinical stagea I vs. II vs. III and IV 10.343 0.006 8.576 0.014
Histological type IDC vs. ILC vs. Others 0.588 0.745 0.883 0.643
Ki-67 LI Low (≤14 %) vs. High (>14 %) 1.974 0.160 2.709 0.100
Chemotherapy AC vs. AC-T vs. Others vs. None 0.664 0.882 1.194 0.754
Radiotherapy No vs. Yes 0.091 0.763 0.002 0.963
PELP1 status Low vs. High 2.887 0.089 3.182 0.074
Abbreviations: LN, lymph node; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Ki-67 LI, Ki-67 label index; AC, Adriamycin/Cyclophosphamide;
AC-T, Adriamycin/Cyclophosphamide-Taxol; DFS, disease-free survival; OS, overall survival
Note: afor the variable, data for two cases are unavailable from medical records
Fig. 3 PELP1 protein expression and patients’ outcome in subgroups of TNBC. Kaplan–Meier survival curve showed that, in the tumor size ≤ 2 cm
subgroup, patients with high PELP1 expression had significantly shorter DFS (a1); in the high Ki-67 LI subgroups, patients with high PELP1 expression
have significantly shorter DFS (b1) and OS (b2).
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metastasis of tumors including breast [21], ovarian [22],
endometrial [23] and prostate cancer [24]. PELP1 had
been reported to interact with several proteins involved
in cell adhesion and extracellular matrix remodeling,
such as Src kinase, PI3K, Integrin-linked kinase 1, and
Metastasis-associated protein 1 [21]. In ER -negative
breast cancer, deregulated PELP1 modulated the tran-
scription of genes involved in epithelial-to-mesenchymal
transition (EMT) and enhanced the activity of matrix
metalloproteinases, thereby promoting tumor invasion
and metastasis. In line with these findings, PELP1
knockdown reduced the in vivo metastatic potential of
ER-negative breast cancer cells and significantly reduced
lung metastasis in an in vivo xenograft assay [10]. Thus,
our finding of a correlation between PELP1 expression
and lymph node metastasis is consistent with previous
studies that documented the oncogenic and pro-
metastatic properties of PELP1 and may explain the
poor prognosis observed in PELP1-expressing, highly
proliferative TNBC tumors.
The prognostic significance of PELP1 varies among
carcinomas, and seems dependent on the cellular con-
text. Early studies proposed PELP1 expression as a pre-
dictor of poor outcome in patients with multiple types
of carcinomas, including breast [14], endometrial [11],
colorectal [13], and prostate cancers [24]. However, the
most recent study examining PELP1 as a prognostic
marker found it was associated with favorable prognosis
in ERβ-positive ovarian cancer [12]. Overall, the diver-
gent results between these studies suggest that PELP1
may have different prognostic impact in settings of
different tumors or possibly within different sub-
groups of the same tumor. In our study, PELP1 did
not show a significant independent association with
either OS or DFS in TNBC patients, though patients
with higher PELP1 expression demonstrated a trend
of reduced DFS and OS, compared with those with
less PELP1 expression (p = 0.089 for DFS, p = 0.074
for OS, log rank test).
As TNBC is inherently a heterogeneous subgroup of
breast cancer, we considered the possibility that further
sub-division of TNBC may be necessary to fully appreci-
ate any potential role of PELP1 [25]. Ki-67, an indicator
of cell proliferation, has been previously used to further
sub-classify TNBC, and breast cancer patients with a
Ki-67 LI >14 % were considered to have poorer out-
comes [15, 26]. In this study, by combining PELP1
status with other clinicopathological variables to cre-
ate a biological marker for predicting prognosis of
TNBC, we found that patients with double high
PELP1/Ki-67 expression (PELP1 H-score ≥170 and
Ki-67 LI >14 %) had significantly reduced OS and
DFS, in comparison with the other subgroups. Multi-
variable analysis also indicated that high expression of
both PELP1 and Ki-67 in TNBC was an independent
prognostic factor, with an adjusted HR of 2.020 for re-
currence (95 % CL, 1.022–3.990; p = 0.043) and 2.380 for
death (95 % CL, 1.138–4.978; p = 0.021). Despite the lim-
ited sample size in the present study, our results still sug-
gest that combining PELP1 and Ki-67 expression as a
biological marker may enhance the prognostic sensitivity
of the two biomarkers in TNBC.
Table 4 Univariate analysis of DFS and OS according to PELP1
protein expression in different subgroups
Variables Subgroup DFS OS
χ2 P-value χ2 P-value
Age (years)
≤50 1.636 0.201 1.759 0.185
>50 1.183 0.277 1.246 0.264
Tumor size (cm)a
≤2 4.274 0.039 3.398 0.065
>2, ≤5 0.441 0.507 0.813 0.367
>5 1.936 0.164 1.134 0.284
Lymph node stage
negative 0.251 0.617 0.008 0.927
positive 0.770 0.380 1.974 0.160
Grade
G1 1.864 0.172 0.688 0.407
G2 2.369 0.124 2.327 0.127
G3 0.188 0.665 0.461 0.497
Clinical stagea
I 1.231 0.267 1.250 0.264
II 0.258 0.612 0.009 0.926
III and IV 1.814 0.178 3.220 0.073
Histological type
IDC 1.278 0.258 1.399 0.237
ILC 1.780 0.182 1.591 0.207
Others 0.928 0.335 0.928 0.335
Ki-67 LI
Low (≤14 %) 0.148 0.700 0.161 0.688
High (>14 %) 5.069 0.024 5.559 0.018
Chemotherapy
AC 1.144 0.285 1.192 0.275
AC-T 1.910 0.157 1.871 0.171
Others 0.000 0.994 0.500 0.480
Radiotherapy
No 2.806 0.094 3.262 0.071
Yes 0.460 0.498 0.488 0.485
Abbreviations: LN, lymph node; IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; Ki-67 LI, Ki-67 label index; AC, Adriamycin/Cyclophosphamide;
AC-T, Adriamycin/Cyclophosphamide-Taxol; DFS, disease-free survival; OS, overall
survival
Note: afor the variable, data for two cases are unavailable from medical records
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In addition to its potential as a prognostic marker,
PELP1 expression has also been suggested as a candidate
therapeutic target for treating hormone-related cancers
[22, 27]. In previous in vitro studies, reduction of PELP1
expression by RNA interference (RNAi) exhibited a sub-
stantial inhibitory effect on proliferation, invasion, and
therapeutic resistance of tumor cells [21, 28–30]. How-
ever, the challenges, such as off-target effects, toxicity and
safe delivery methods, associated with the clinical applica-
tion of RNAi-based therapeutics remain. Therefore, at this
juncture, RNAi is not yet considered a viable therapeutic
approach [31]. However, recent studies have indicated that
this may change. For example, a team from The University
of Texas reported the development of a novel, stable, non-
toxic, small molecule peptidomimetic, which can disrupt
the specific interaction between PELP1 and the androgen
receptor and demonstrates a functional abrogation of
androgen-induced proliferation of prostate cancer cells
[32]. This finding suggests a promising future for PELP1-
targeted therapy, but whether this small molecule peptido-
mimetic will also work against breast cancer, especially in
TNBC cases, still needs further investigation.
Conclusions
Despite the limitation of a small sample size used in this
study, our findings indicate that considering PELP1 and
Fig. 4 Combining PELP1 status and Ki-67 LI as a prognostic biological marker. Kaplan–Meier survival curve showed that, combination of PELP1
status with Ki-67 status was significantly correlated with DFS (a1) and OS (a2) in patients with TNBC; patients with TNBC in PELP1/Ki-67 double
high group had significantly reduced DFS (b1) and OS (b2) compared with others.
Table 5 Multivariate analysis of DFS and OS according to clinical pathological variables
Variables DFS OS
HR 95 % CL P-value HR 95 % CL P-value
Age (years) ≤50 vs. >50 0.786 0.404-1.527 0.477 0.698 0.340-1.432 0.327
Tumor size (cm)a ≤2 vs. >2, ≤5 vs. >5 1.283 0.721-2.281 0.397 1.405 0.760-2.598 0.279
Lymph node stage negative vs. positive 2.167 0.980-4.796 0.056 2.001 0.864-4.637 0.106
Grade G1 vs. G2 vs. G3 1.286 0.756-2.186 0.353 1.273 0.722-2.246 0.404
Histological type IDC vs. ILC vs. Others 0.742 0.422-1.306 0.301 0.651 0.345-1.228 0.185
Combined grouping others vs. PELP1, Ki-67 double high 2.020 1.022-3.990 0.043 2.380 1.138-4.978 0.021
Abbreviations: LN, lymph node; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; 95 % CL, 95 % confidence interval
Note: afor the variable, data for two cases are unavailable from medical records
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Ki-67 expression systemically in TNBC will enhance the
prognostic sensitivity of the two biomarkers, as high
expression of both PELP1 and Ki-67 in tumors is an in-
dependent prognostic factor predicting poorer outcome
of patients with TNBC. Furthermore, this finding sug-
gests that PELP1 may be a valuable therapeutic target
for TNBC in the future.
Abbreviations
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LI: Ki-67 label index; LN: Lymph node; OS: Overall survival; PELP1: Proline,
glutamic acid, leucine rich protein 1; PI3K: Phosphatidylinositol 3-kinase;
PR: Progesterone receptor; TNBC: Triple-negative breast cancer.
Competing interests
We have no conflicts of interest to declare.
Authors’ contributions
YZZ, JLD, ML, SWC, YCX and BSZ performed the research; LW, KMM, MSMC,
HS, BB and YLS designed the research study; MMS, XLL and XLW analyzed
the data; LJL and YM wrote the paper. All authors read and approved the
final manuscript.
Acknowledgements
This project was supported by the Natural Science Foundation of Heilongjiang
Province, China (Grant No. D200871), Foundation of Heilongjiang Educational
Committee, China (Grant No.12521237) and Innovation Fund Project for
Graduate Student of Heilongjiang, China (Grant No.YJSCX2012-220HLJ).
Author details
1Department of Pathology, Harbin Medical University-Daqing, No. 39 Xinyang
Road, Hi-Tech Zone, Daqing, Heilongjiang, China. 2Department of Pathology,
Tohoku University School of Medicine, Sendai, Japan. 3Department of
Histology and Biology, Harbin Medical University-Daqing, Daqing, China.
4Department of Pathology, The Fifth Affiliated Hospital of Harbin Medical
University, Daqing, China. 5Department of Pathology, Daqing Oilfield General
Hospital, Daqing, China. 6Department of Pathology, Daqing Longnan
Hospital, Daqing, China.
Received: 2 March 2015 Accepted: 7 October 2015
References
1. Cancer Genome Atlas N. Comprehensive molecular portraits of human
breast tumours. Nature. 2012;490(7418):61–70.
2. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical
needs. Breast Cancer Res Treat. 2011;125(3):627–36.
3. de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC.
Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol.
2011;137(2):183–92.
4. Zagouri F, Bago-Horvath Z, Rossler F, Brandstetter A, Bartsch R, Papadimitriou
CA, et al. High MET expression is an adverse prognostic factor in patients with
triple-negative breast cancer. Br J Cancer. 2013;108(5):1100–5.
5. Koh YW, Lee HJ, Ahn JH, Lee JW, Gong G. Expression of Lewis X is
associated with poor prognosis in triple-negative breast cancer. Am J Clin
Pathol. 2013;139(6):746–53.
6. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, et al.
Outcome of triple-negative breast cancer in patients with or without
deleterious BRCA mutations. Breast Cancer Res Treat. 2011;130(1):145–53.
7. Brann DW, Zhang QG, Wang RM, Mahesh VB, Vadlamudi RK. PELP1–a
novel estrogen receptor-interacting protein. Mol Cell Endocrinol.
2008;290(1–2):2–7.
8. Nair S, Vadlamudi RK. Emerging significance of ER-coregulator PELP1/MNAR
in cancer. Histol Histopathol. 2007;22(1):91–6.
9. Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR, Vadlamudi RK.
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic
acid-, leucine-rich protein 1/modulator of the nongenomic actions of the
estrogen receptor. Cancer Res. 2007;67(11):5505–12.
10. Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A,
Ahn JM, et al. Significance of PELP1 in ER-negative breast cancer metastasis.
Molecular cancer research : MCR. 2012;10(1):25–33.
11. Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA, Kumar R.
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and
leucine-rich protein-1/modulator of nongenomic activity of estrogen
receptor in human endometrial tumors. J Clin Endocrinol Metab.
2004;89(12):6130–8.
12. Aust S, Horak P, Pils D, Pils S, Grimm C, Horvat R, et al. The prognostic
value of estrogen receptor beta and proline-, glutamic acid- and
leucine-rich protein 1 (PELP1) expression in ovarian cancer. BMC
Cancer. 2013;13:115.
13. Grivas PD, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou
AG, Kalofonos H. Expression of ERalpha, ERbeta and co-regulator PELP1/
MNAR in colorectal cancer: prognostic significance and clinicopathologic
correlations. Cell Oncol. 2009;31(3):235–47.
14. Habashy HO, Powe DG, Rakha EA, Ball G, Macmillan RD, Green AR, et al. The
prognostic significance of PELP1 expression in invasive breast cancer with
emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat.
2010;120(3):603–12.
15. Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N,
Serrano D, et al. Tailoring treatment for ductal intraepithelial neoplasia
of the breast according to Ki-67 and molecular phenotype. Br J Cancer.
2013;108(8):1593–601.
16. Gururaj AE, Peng S, Vadlamudi RK, Kumar R. Estrogen induces expression
of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-,
glutamic acid-, and leucine-rich protein-1 (PELP1). Mol Endocrinol.
2007;21(8):1847–60.
17. Mann M, Cortez V, Vadlamudi R. PELP1 oncogenic functions involve CARM1
regulation. Carcinogenesis. 2013;34(7):1468–75.
18. Vadlamudi RK, Wang RA, Mazumdar A, Kim Y, Shin J, Sahin A, et al.
Molecular cloning and characterization of PELP1, a novel human
coregulator of estrogen receptor alpha. J Biol Chem.
2001;276(41):38272–9.
19. Williams MD, Roberts D, Blumenschein Jr GR, Temam S, Kies MS,
Rosenthal DI, et al. Differential expression of hormonal and growth
factor receptors in salivary duct carcinomas: biologic significance and
potential role in therapeutic stratification of patients. Am J Surg Pathol.
2007;31(11):1645–52.
20. Boonyaratanakornkit V. Scaffolding proteins mediating membrane-initiated
extra-nuclear actions of estrogen receptor. Steroids. 2011;76(9):877–84.
21. Chakravarty D, Nair SS, Santhamma B, Nair BC, Wang L, Bandyopadhyay A,
et al. Extranuclear functions of ER impact invasive migration and metastasis
by breast cancer cells. Cancer Res. 2010;70(10):4092–101.
22. Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, et al.
Therapeutic targeting of PELP1 prevents ovarian cancer growth and
metastasis. Clin Cancer Res. 2011;17(8):2250–9.
23. Wan J, Li X. PELP1/MNAR suppression inhibits proliferation and metastasis
of endometrial carcinoma cells. Oncol Rep. 2012;28(6):2035–42.
24. Yang L, Ravindranathan P, Ramanan M, Kapur P, Hammes SR, Hsieh JT, et al.
Central role for PELP1 in nonandrogenic activation of the androgen
receptor in prostate cancer. Mol Endocrinol. 2012;26(4):550–61.
25. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic
markers in triple-negative breast cancer. Cancer. 2007;109(1):25–32.
26. Matsubara N, Mukai H, Itoh K, Nagai S. Prognostic impact of Ki-67
overexpression in subgroups categorized according to St. Gallen with early
stage breast cancer. Oncology. 2011;81(5–6):345–52.
27. Renoir JM, Marsaud V, Lazennec G. Estrogen receptor signaling as
a target for novel breast cancer therapeutics. Biochem Pharmacol.
2013;85(4):449–65.
28. Wang J, Song S, Shi L, Zhu Q, Ma C, Tan X, et al. Temporal Expression of
Pelp1 during Proliferation and Osteogenic Differentiation of Rat Bone
Marrow Mesenchymal Stem Cells. PLoS One. 2013;8(10):e75477.
29. Nair BC, Nair SS, Chakravarty D, Challa R, Manavathi B, Yew PR, et al.
Cyclin-dependent kinase-mediated phosphorylation plays a critical
role in the oncogenic functions of PELP1. Cancer Res.
2010;70(18):7166–75.
Zhang et al. BMC Cancer  (2015) 15:699 Page 10 of 11
30. Manavathi B, Nair SS, Wang RA, Kumar R, Vadlamudi RK. Proline-, glutamic
acid-, and leucine-rich protein-1 is essential in growth factor regulation of
signal transducers and activators of transcription 3 activation. Cancer Res.
2005;65(13):5571–7.
31. Petrocca F, Lieberman J. Promise and challenge of RNA interference-based
therapy for cancer. J Clin Oncol. 2011;29(6):747–54.
32. Ravindranathan P, Lee TK, Yang L, Centenera MM, Butler L, Tilley WD, et al.
Peptidomimetic targeting of critical androgen receptor-coregulator
interactions in prostate cancer. Nat Commun. 2013;4:1923.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. BMC Cancer  (2015) 15:699 Page 11 of 11
